Interferon-Free Hepatitis C Regimens Within Reach
Executive Summary
Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.
You may also be interested in...
Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
Gilead reported results from three Phase III trials in February, with data strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.
Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
Gilead released Phase III data Feb. 4 strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.
Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected
Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.